相似文献
1
Fingolimod reduces hemorrhagic transformation associated with delayed tissue plasminogen activator treatment in a mouse thromboembolic model.
Stroke. 2013 Feb;44(2):505-11. doi: 10.1161/STROKEAHA.112.679043. Epub 2013 Jan 3.
2
IMM-H004 prevents toxicity induced by delayed treatment of tPA in a rat model of focal cerebral ischemia involving PKA-and PI3K-dependent Akt activation.
Eur J Neurosci. 2014 Jun;39(12):2107-18. doi: 10.1111/ejn.12551. Epub 2014 Mar 20.
3
Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: combination studies with the thrombolytic tissue plasminogen activator.
Stroke. 2001 Jan;32(1):147-53. doi: 10.1161/01.str.32.1.147.
4
Toll-Like Receptor 4 Mediates Hemorrhagic Transformation After Delayed Tissue Plasminogen Activator Administration in In Situ Thromboembolic Stroke.
Stroke. 2017 Jun;48(6):1695-1699. doi: 10.1161/STROKEAHA.116.015956. Epub 2017 Apr 20.
5
Fingolimod provides long-term protection in rodent models of cerebral ischemia.
Ann Neurol. 2011 Jan;69(1):119-29. doi: 10.1002/ana.22186. Epub 2010 Nov 12.
6
A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
Stroke. 2011 Jan;42(1):196-203. doi: 10.1161/STROKEAHA.110.600452. Epub 2010 Nov 24.
7
Effects of the spin trap agent disodium- [tert-butylimino)methyl]benzene-1,3-disulfonate N-oxide (generic NXY-059) on intracerebral hemorrhage in a rabbit Large clot embolic stroke model: combination studies with tissue plasminogen activator.
Stroke. 2002 Jun;33(6):1665-70. doi: 10.1161/01.str.0000017145.22806.aa.
8
Phthalide derivative CD21 attenuates tissue plasminogen activator-induced hemorrhagic transformation in ischemic stroke by enhancing macrophage scavenger receptor 1-mediated DAMP (peroxiredoxin 1) clearance.
J Neuroinflammation. 2021 Jun 24;18(1):143. doi: 10.1186/s12974-021-02170-7.
9
Inhibition of tPA-induced hemorrhagic transformation involves adenosine A2b receptor activation after cerebral ischemia.
Neurobiol Dis. 2017 Dec;108:173-182. doi: 10.1016/j.nbd.2017.08.011. Epub 2017 Aug 19.
10
Role of the S1P pathway and inhibition by fingolimod in preventing hemorrhagic transformation after stroke.
Sci Rep. 2019 Jun 5;9(1):8309. doi: 10.1038/s41598-019-44845-5.
引用本文的文献
1
Asparagine Endopeptidase Inhibition Attenuates Tissue Plasminogen Activator-Induced Brain Hemorrhagic Transformation After Ischemic Stroke.
CNS Neurosci Ther. 2025 Mar;31(3):e70345. doi: 10.1111/cns.70345.
2
The mechanism of microglia-mediated immune inflammation in ischemic stroke and the role of natural botanical components in regulating microglia: A review.
Front Immunol. 2023 Feb 2;13:1047550. doi: 10.3389/fimmu.2022.1047550. eCollection 2022.
3
Need for a Paradigm Shift in the Treatment of Ischemic Stroke: The Blood-Brain Barrier.
Int J Mol Sci. 2022 Aug 22;23(16):9486. doi: 10.3390/ijms23169486.
4
Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities.
Front Pharmacol. 2022 Jul 13;13:920449. doi: 10.3389/fphar.2022.920449. eCollection 2022.
5
Orally Administered Brain Protein Combined With Probiotics Increases Treg Differentiation to Reduce Secondary Inflammatory Damage Following Craniocerebral Trauma.
Front Immunol. 2022 Jul 6;13:928343. doi: 10.3389/fimmu.2022.928343. eCollection 2022.
6
Selective sphingosine-1-phosphate receptor 1 modulator attenuates blood-brain barrier disruption following traumatic brain injury by inhibiting vesicular transcytosis.
Fluids Barriers CNS. 2022 Jul 11;19(1):57. doi: 10.1186/s12987-022-00356-6.
7
Molecular Pharmacology and Novel Potential Therapeutic Applications of Fingolimod.
Front Pharmacol. 2022 Feb 16;13:807639. doi: 10.3389/fphar.2022.807639. eCollection 2022.
8
Sonosensitive capsules for brain thrombolysis increase ischemic damage in a stroke model.
J Nanobiotechnology. 2022 Jan 21;20(1):46. doi: 10.1186/s12951-022-01252-9.
9
Hemorrhagic Transformation After Ischemic Stroke: Mechanisms and Management.
Front Neurol. 2021 Nov 30;12:703258. doi: 10.3389/fneur.2021.703258. eCollection 2021.
10
Sphingosine-1-Phosphate Signaling in Ischemic Stroke: From Bench to Bedside and Beyond.
Front Cell Neurosci. 2021 Nov 30;15:781098. doi: 10.3389/fncel.2021.781098. eCollection 2021.
本文引用的文献
1
Reperfusion therapy for acute stroke improves outcome by decreasing neuroinflammation.
Transl Stroke Res. 2010 Dec;1(4):261-7. doi: 10.1007/s12975-010-0038-0. Epub 2010 Aug 28.
2
Fingolimod for multiple sclerosis.
N Engl J Med. 2012 Jan 26;366(4):339-47. doi: 10.1056/NEJMct1101691.
3
Migraine mutations increase stroke vulnerability by facilitating ischemic depolarizations.
Circulation. 2012 Jan 17;125(2):335-45. doi: 10.1161/CIRCULATIONAHA.111.045096. Epub 2011 Dec 5.
4
Activation of sphingosine kinase 2 is an endogenous protective mechanism in cerebral ischemia.
Biochem Biophys Res Commun. 2011 Sep 23;413(2):212-7. doi: 10.1016/j.bbrc.2011.08.070. Epub 2011 Aug 22.
5
FTY720 reduces post-ischemic brain lymphocyte influx but does not improve outcome in permanent murine cerebral ischemia.
PLoS One. 2011;6(6):e21312. doi: 10.1371/journal.pone.0021312. Epub 2011 Jun 20.
6
Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis.
Ann Neurol. 2011 May;69(5):759-77. doi: 10.1002/ana.22426.
7
The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators.
Neurology. 2011 Feb 22;76(8 Suppl 3):S9-14. doi: 10.1212/WNL.0b013e31820d9507.
8
Fingolimod provides long-term protection in rodent models of cerebral ischemia.
Ann Neurol. 2011 Jan;69(1):119-29. doi: 10.1002/ana.22186. Epub 2010 Nov 12.
9
A mouse model of hemorrhagic transformation by delayed tissue plasminogen activator administration after in situ thromboembolic stroke.
Stroke. 2011 Jan;42(1):196-203. doi: 10.1161/STROKEAHA.110.600452. Epub 2010 Nov 24.
10
Equipoise among recanalization strategies.
Neurology. 2010 Mar 30;74(13):1069-76. doi: 10.1212/WNL.0b013e3181d76b8f.
Zotero 插件